Klotho half-life & pharmacokinetics

Reported half-life

Variable across Klotho preparations. The transmembrane full-length protein has tissue-membrane residence rather than circulating half-life. The soluble ~65-70 kDa extracellular domain generated by proteolytic cleavage circulates in plasma with plasma half-life of hours; recombinant soluble Klotho preparations have been engineered for various half-life profiles depending on the specific development context.

The half-life and pharmacokinetic profile of Klotho reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Intravenous infusion (research; clinical exploration)
• Subcutaneous injection (research)
• Gene therapy approaches (pre-clinical exploration)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Single-pass transmembrane glycoprotein; FGF23 co-receptor for phosphate homeostasis with additional independent effects on IGF-1 signalling, oxidative stress, and cellular protection; longevity gene product.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Klotho acts as follows:

Klotho is a single-pass transmembrane glycoprotein encoded by the KL gene, discovered by Makoto Kuro-o and colleagues in 1997 through the striking observation that homozygous KL gene mutation in mice produces a dramatic accelerated-ageing phenotype resembling human progeria — with substantially shortened lifespan, arteriosclerosis, skin atrophy, osteoporosis, pulmonary emphysema, and impaired reproduction. The gene was named for Klotho, the Greek Fate who spins the thread of life at birth, reflecting its established role as a foundational longevity gene. The remarkable severity of the Klotho-knockout phenotype established Klotho as one of the most-validated longevity-related genetic targets in mammalian biology.

See the full Klotho research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.